Literature DB >> 31741178

Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis: A Proposed Guided Dose-Reduction Algorithm.

Chen-Chung Liu1,2, Hiroyoshi Takeuchi3,4.   

Abstract

Continuing antipsychotic treatment in patients with schizophrenia under clinical remission remains controversial. Even though the mainstream opinion declares an outweighed balance against medication discontinuation, recent reviews and critiques suggest that some patients may remain symptom free and well functioning after stopping antipsychotics, but few predictors can identify who can try medication discontinuation, whilst no guidelines exist for reducing medication to reach the lowest effective dose safely. Analyzing the findings from studies employing different methodologies, adopting evidence from pharmacodynamic research, and observing dose reduction in stable patients, as well as taking inspiration from the metaphor of the Cantor set in natural philosophy, we introduce an alternative solution and propose a guided dose-reduction algorithm that follows a set of clear precautions and instructions. The algorithm recommends only a fraction (no more than 25%) of the dosage to be reduced at a time, with at least a 6-month stabilization period required before reducing another 25% of the dose. Patients are empowered to actively participate in decision making when they are ready for further dose tapering, or should they retreat to a previous dosage if warning signs of a relapse re-emerge. An intermittent or irregular dosing schedule can be used to adapt this algorithm to real-world practice. Our preliminary findings suggest that patients with remitted psychosis can do well along this path. We anticipate that this approach can help optimize the risk-benefit ratio and instill a hope in patients with schizophrenia that they can maintain in stable remission under a lower antipsychotic dose without an increased risk of relapse.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31741178     DOI: 10.1007/s40263-019-00682-8

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  90 in total

Review 1.  Early detection and intervention in first-episode schizophrenia: a critical review.

Authors:  T K Larsen; S Friis; U Haahr; I Joa; J O Johannessen; I Melle; S Opjordsmoen; E Simonsen; P Vaglum
Journal:  Acta Psychiatr Scand       Date:  2001-05       Impact factor: 6.392

Review 2.  Prospective investigations of the prodromal state of schizophrenia: review of studies.

Authors:  K A Olsen; B Rosenbaum
Journal:  Acta Psychiatr Scand       Date:  2006-04       Impact factor: 6.392

3.  Recruitment and treatment practices for help-seeking "prodromal" patients.

Authors:  Thomas H McGlashan; Jean Addington; Tyrone Cannon; Markus Heinimaa; Patrick McGorry; Mary O'Brien; David Penn; Diana Perkins; Raimo K R Salokangas; Barbara Walsh; Scott W Woods; Alison Yung
Journal:  Schizophr Bull       Date:  2007-05-04       Impact factor: 9.306

4.  The Effect of Antipsychotic Treatment on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies.

Authors:  Antonio Vita; Luca De Peri; Giacomo Deste; Stefano Barlati; Emilio Sacchetti
Journal:  Biol Psychiatry       Date:  2015-02-16       Impact factor: 13.382

5.  Long-term antipsychotic treatment of schizophrenia: does it help or hurt over a 20-year period?

Authors:  Martin Harrow; Thomas H Jobe
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

6.  Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.

Authors:  Jacqueline Mayoral-van Son; Victor Ortiz-Garcia de la Foz; Obdulia Martinez-Garcia; Teresa Moreno; Maria Parrilla-Escobar; Elsa M Valdizan; Benedicto Crespo-Facorro
Journal:  J Clin Psychiatry       Date:  2016-04       Impact factor: 4.384

Review 7.  The prodromal phase of first-episode psychosis: past and current conceptualizations.

Authors:  A R Yung; P D McGorry
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

8.  Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.

Authors:  Diana O Perkins; Hongbin Gu; Peter J Weiden; Joseph P McEvoy; Robert M Hamer; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2008-01       Impact factor: 4.384

9.  Increasing expectations and knowledge require a more subtle use of prophylactic antipsychotics.

Authors:  Robin M Murray; Marta Di Forti
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

10.  Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies.

Authors:  P Fusar-Poli; R Smieskova; M J Kempton; B C Ho; N C Andreasen; S Borgwardt
Journal:  Neurosci Biobehav Rev       Date:  2013-06-14       Impact factor: 8.989

View more
  1 in total

1.  A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

Authors:  Mark Abie Horowitz; Sameer Jauhar; Sridhar Natesan; Robin M Murray; David Taylor
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 7.348

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.